Why Sokhom Pin Never Left GPCRs, Even When Everyone Else Did
- Dr. GPCR Podcast
- Jul 17
- 1 min read
Trends come and go. Scientific fads rise and fall. But Sokhom Pin stayed loyal to GPCRs, even when big pharma turned its gaze to other targets like kinases and checkpoint inhibitors.
Riding the GPCR Rollercoaster
Early in his career at DuPont and BMS, GPCRs were red hot. High-throughput screening for receptor ligands was booming, and Sokhom was at the center of it.
But then came the industry shift.
“Companies started shutting down neuroscience and GPCR programs. But I stayed,” Sokhom said.
While others pivoted, Sokhom went deeper: refining assays, exploring signaling bias, and building a robust knowledge base in one of the most pharmacologically diverse receptor families.
The Payoff of Staying Focused
Today, GPCRs are making a comeback in popularity. Advances in biased signaling, allosterism, and endosomal signaling have opened new therapeutic frontiers. And Sokhom? He’s one of the few who never left.
“Because the field became unpopular for a while, they stopped training new experts. Now, there’s less competition and more opportunity.”
A Career Built on Consistency
From CGRP receptor antagonists at BMS to opioid receptor research at Alkermes and early-stage work at Cerevel and Superluminal, Sokhom’s consistency has paid off in ways short-term thinkers often miss.
_______________
Commentaires